Lundbeck fine: industry outraged over messy patent system
This article was originally published in Scrip
Lundbeck has branded as "erroneous" the European Commission's decision to fine it for anticompetitive behavior, while the European industry federation , EFPIA, has claimed that the affair flags up deficiencies in the European patent litigation system and raises cause for concern with implications for innovation, patient welfare and economic growth.
You may also be interested in...
The EU’s General Court has upheld the European Commission’s decision to fine Lundbeck and a number of generics firms for agreeing to keep generic versions of the antidepressant citalopram off the market in return for payments. The ruling could have implications for other similar cases such as that involving GlaxoSmithKline’s paroxetine in the UK.
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.